Inflarx NV (IFRX) Study Beat Raymond James' Expectations Despite Statistical Significance Miss
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse reiterated a Strong Buy on Inflarx NV (NASDAQ: IFRX), saying while the Phase 3 COVID-19 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
